α2c adrenoreceptor program

The α2c adrenoreceptor program is a preclinical drug discovery initiative led by the Warren Center for Neuroscience Drug Discovery (WCNDD) at Vanderbilt University. The program focuses on the development of small molecule modulators of the α2c-adrenergic receptor (ADRA2C) for the treatment of Major Depressive Disorder (MDD). The α2c-adrenoceptor is a G protein-coupled receptor primarily localized in the central nervous system, where it plays a significant role in regulating the release of neurotransmitters such as norepinephrine and dopamine. While the specific functional direction (agonist vs. antagonist) is not explicitly detailed in the center's pipeline, α2c-adrenoceptor antagonists are traditionally investigated for their potential antidepressant and antipsychotic-like properties. The program is currently in the hit-to-lead stage of development.